Innovation
Exeliom Biosciences: a new generation of microbiota-derived biotherapies
… a specific bacterium, Faecalibacterium prausnitzii (Fprau), was consistently absent in patients experiencing a relapse … in the journal PNAS , and now cited more than 4,000 times, established for the first time the immunomodulatory … makes it possible to deliver a precise dose in gastro-resistant capsule form and marks the achievement of an industrial …
Published on: